多西他赛联合卡培他滨化疗治疗进展期胃癌术后研究.docVIP

多西他赛联合卡培他滨化疗治疗进展期胃癌术后研究 　　[摘要] 目的 探析多西他赛联合卡培他滨化疗治疗进展期胃癌术后的临床效果。方法 方便选取该院2010年3月―2014年3月收治的126例进展期胃癌术后患者，将其随机分为研究组和对照组，各63例，对照组采取多西他赛+奥沙利铂+5-氟尿嘧啶/CF方案，研究组采取多西他赛联合卡培他滨方案，比较两组1、3年生存率及不良反应发生率。结果 研究组1年生存率81.0%、3年生存率61.9%与对照组60.3%、38.1%比较差异有统计学意义（P0.05）。结论 多西他赛联合卡培他滨化疗治疗进展期胃癌术后的临床效果明显，患者生存率比较高，耐受性好，值得临床推广。 　　[关键词] 多西他赛；卡培他滨；进展期；胃癌术后；临床效果 　　[中图分类号] R735 [文献标识码] A [文章编号] 1674-0742（2017）04（a）-0144-03 　　Research on Docetaxel Combined with Capecitabine Chemotherapy for Advanced Gastric Cancer 　　CHEN Ming-xiang 　　Department of Medical Oncology， Yizheng People’s Hospital， Yizheng， Jiangsu Province， 211400 China 　　[Abstract] Objective To study the clinical effect of docetaxel combined with capecitabine chemotherapy for advanced gastric cancer. Methods Convenient selection 126 cases of patients with advanced gastric cancer admitted and treated in our hospital from March 2010 to March 2014 were selected and randomly divided into two groups with 63 cases in each， the control group adopted the docetaxel and oxaliplatin and 5 fluorouracil/CF plan， while the research group adopted the docetaxel combined with capecitabine plan， and the 1-year and 3-year survival rates and incidence rate of adverse reactions were compared between the two groups. Results The differences in the 1-year and 3-year survival rates between the research group and the control group were obvious（81.0%， 61.9% vs 60.3%， 38.1%）（P0.05）. Conclusion The clinical effect of docetaxel combined with capecitabine chemotherapy for advanced gastric cancer is obvious with high survival rate of patients and good tolerance， which is worth clinical promotion. 　　[Key words] Docetaxel； Capecitabine； Advanced； After the gastric cancer surgery； Clinical effect 　　胃癌是?R床上十分常见的恶性肿瘤，其患病率及死亡率均比较高，且多数患者确诊时，其病情已处于晚期。临床上对于胃癌的治疗多采取手术治疗，且具有一定的效果，相关研究显示[1]，对于处于进展期胃癌患者在行根治性手术后，患者会出现复发的情况，导致生存率降低，而术后联合化疗，能够显著延长患者生存时间，为探析多西他赛联合卡培他滨化疗治疗进展期胃癌术后的临床效果，该文将2010年3月―2014年3月收治的126例进展期胃癌术后患者，作为研究对象，现报道如下。 　　1 资料与方法 　　1.1 一般资料 　　方便选取该院收治的126例进展期胃